ロード中...
Tumor lysis with LTX-401 creates anticancer immunity
Local immunotherapies such as the intratumoral injection of oncolytic compounds aim at reinstating and enhancing systemic anticancer immune responses. LTX-315 is a first-in-class, clinically evaluated oncolytic peptide-based local immunotherapy that meets these criteria. Here, we show that LTX-401,...
保存先:
| 出版年: | Oncoimmunology |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6527292/ https://ncbi.nlm.nih.gov/pubmed/31143516 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2019.1594555 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|